Latest news
Notice of Annual General Meeting 2019
Oslo, Norway 8 May 2019 – The shareholders of PCI Biotech Holding ASA are invited to attend the Annual General Meeting 2019 at Oslo Cancer Cluster Innovation Park. Time: Wednesday May 29, 10am CEST (local time). Venue: Jónas Einarsson Auditorium (2nd floor, entrance 2B), Oslo Cancer Cluster Innovation Park, Ullernchausséen 64, Oslo, Norway. The notice […]
First quarter 2019 results
Oslo (Norway), 8 May 2019 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announces its first quarter 2019 result. Please find enclosed the report and presentation. First sites for the pivotal fimaCHEM “RELEASE” study open for enrolment and successful translation of fimaVACC into man. Final confirmation of safety with two treatments was […]
Successful clinical translation of the fimaVACC technology
Oslo (Norway), 2 May 2019 – PCI Biotech (OSE: PCIB), a cancer focused clinical-stage company developing innovative therapeutics that address significant unmet medical needs today announced that the final immune response results from the fimaVacc Phase I study in healthy volunteers indicate a clear enhancement of both CD8 and CD4 T-cell responses and an improved […]